BWP
LGND icon

Baldwin Wealth Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Baldwin Wealth Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$288K Buy
+911
New +$215K 0.02% 191
2024
Q4 		– Sell
-3,595
Closed -$360K – 673
2024
Q3 		$360K Buy
+3,595
New +$362K 0.02% 246

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
IP
Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Baldwin Wealth Partners's LGND Position: Q2 2026 in Review

Baldwin Wealth Partners opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 911 shares worth $288K. The stake represents 0.02% of the portfolio and ranks #191 among its holdings. This is a return to the name: Baldwin Wealth Partners previously reported a position in LGND as recently as Q3 2024.

Baldwin Wealth Partners first reported a position in LGND in Q3 2024 and has held it in 2 quarters since. The position peaked at $360K in Q3 2024. 61 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Baldwin Wealth Partners held 911 shares of Ligand Pharmaceuticals worth $288K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Baldwin Wealth Partners position in Q2 2026.
  • Ligand Pharmaceuticals made up 0.02% of Baldwin Wealth Partners's portfolio in Q2 2026, its #191 holding.
  • Baldwin Wealth Partners first reported a position in Ligand Pharmaceuticals in Q3 2024 and has held it in 2 quarters since.
  • Baldwin Wealth Partners's Ligand Pharmaceuticals position peaked at $360K in Q3 2024.
  • 61 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Baldwin Wealth Partners's 13F filing for Q2 2026, filed 14 Jul 2026.